10x Genomics (TXG) Common Equity (2018 - 2026)

10x Genomics has disclosed Common Equity across 9 years of filings, most recently posting $825.5 million for Q2 2026.

• In Q2 2026, Common Equity rose 6.76% year-over-year to $825.5 million; the TTM figure through Jun 2026 stood at $825.5 million (up 6.76% YoY), while the FY2025 annual figure was $796.3 million, up 12.14% from the prior year.
• Common Equity came in at $825.5 million for Q2 2026 at 10x Genomics, up from $814.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $825.5 million in Q2 2026 to a low of $706.9 million in Q1 2025.
• Average Common Equity over 5 years is $768.4 million, with a median of $779.7 million recorded in 2022.
• Year-over-year, Common Equity fell 10.41% in 2024 and advanced 15.2% in 2026.
• Over 5 years, Common Equity stood at $805.7 million in 2022, then slipped by 8.03% to $741.0 million in 2023, then dropped by 4.17% to $710.1 million in 2024, then increased by 12.14% to $796.3 million in 2025, then gained by 3.67% to $825.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $825.5 million in Q2 2026, $814.3 million in Q1 2026, and $796.3 million in Q4 2025.